Joachim Alfer
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
von Minckwitz G, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, Simon E, Stickeler E, Potenberg J, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marme F, German Breast Group Investigators. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer 2015; 121:3639-48.
25.06.2015A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)
25.06.2015Cancer 2015; 121:3639-48
von Minckwitz Gunter, Thomssen Christoph, Huober Jens, Denkert Carsten, Alfer Joachim, Jackisch Christian, Nekljudova Valentina, Burchardi Nicole, Loibl Sibylle, Simon Eike, Stickeler Elmar, Potenberg Jochem, Conrad Bettina, Reimer Toralf, Decker Thomas, Eidtmann Holger, Eiermann Wolfgang, Hackmann John, Möbus Volker, Marme Frederik, German Breast Group Investigators
Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer
Bertz S, Abee C, Schwarz-Furlan S, Alfer J, Hofstädter F, Stoehr R, Hartmann A, Gaumann A. Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer. Virchows Arch 2014; 465:687-95.
19.10.2014Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer
19.10.2014Virchows Arch 2014; 465:687-95
Bertz Simone, Abee Christine, Schwarz-Furlan Stephan, Alfer Joachim, Hofstädter Ferdinand, Stoehr Robert, Hartmann Arndt, Gaumann Andreas K A